dc.contributor.author | Duijzer, Daniël | |
dc.contributor.author | de Winter, Maria A. | |
dc.contributor.author | Carrier, Marc | |
dc.contributor.author | Cohen, Alexander T. | |
dc.contributor.author | Hansen, John Bjarne | |
dc.contributor.author | Kaasjager, Karin A.H. | |
dc.contributor.author | Kakkar, Ajay K. | |
dc.contributor.author | Middeldorp, Saskia | |
dc.contributor.author | Sørensen, Henrik T. | |
dc.contributor.author | Visseren, Frank L.J. | |
dc.contributor.author | Wells, Philip S. | |
dc.contributor.author | Dorresteijn, Jannick A.N. | |
dc.contributor.author | Nijkeuter, Mathilde | |
dc.date.accessioned | 2024-11-13T13:28:51Z | |
dc.date.available | 2024-11-13T13:28:51Z | |
dc.date.issued | 2024-09-11 | |
dc.description.abstract | Background - After 3 months of anticoagulation for venous thromboembolism (VTE), the decision needs to be made whether to stop anticoagulation or extend treatment indefinitely. The VTE-PREDICT calculator can be used to estimate individual risks of VTE recurrence and bleeding to guide this decision.<p>
<p>Objectives - To evaluate the impact of predicted individual risks of recurrence and bleeding on clinicians’ decisions on anticoagulation duration and to assess usefulness of the VTE-PREDICT calculator.<p>
<p>Methods - A randomized controlled trial and within-subject study was conducted among clinicians treating VTE patients. The clinicians were asked to complete an online survey containing 6 fictional case vignettes. Group A proposed anticoagulant duration for each case without additional information first and subsequently after seeing calculator-predicted risks (within-subject analysis). Group B was directly provided with calculator risks and proposed treatment duration for each case vignette (for comparison with group A results in a randomized controlled trial analysis). Then, group B received questions on usefulness and credibility of the calculator.<p>
<p>Results - Forty-five clinicians were assigned to group A and 48 to B. Overall, group A did not propose different anticoagulation durations than group B. However, individual clinicians in group A changed proposed duration in 35% of the cases after seeing the calculator risks. The calculator was considered useful and credible by most clinicians.<p>
<p>Conclusion - Overall, use of the VTE-PREDICT calculator did not affect proposed anticoagulation duration. However, individual clinicians frequently changed their proposed duration after using the calculator, especially for patients with high bleeding risk. | en_US |
dc.identifier.citation | Duijzer, de Winter, Carrier, Cohen, Hansen, Kaasjager, Kakkar, Middeldorp, Sørensen, Visseren, Wells, Dorresteijn, Nijkeuter. Impact of the VTE-PREDICT calculator on clinicians’ decision making in fictional patients with venous thromboembolism: a randomized controlled trial. Research and Practice in Thrombosis and Haemostasis (RPTH). 2024;8(7) | |
dc.identifier.cristinID | FRIDAID 2313404 | |
dc.identifier.doi | 10.1016/j.rpth.2024.102569 | |
dc.identifier.issn | 2475-0379 | |
dc.identifier.uri | https://hdl.handle.net/10037/35703 | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.journal | Research and Practice in Thrombosis and Haemostasis (RPTH) | |
dc.rights.holder | Copyright 2024 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_US |
dc.rights | Attribution 4.0 International (CC BY 4.0) | en_US |
dc.title | Impact of the VTE-PREDICT calculator on clinicians’ decision making in fictional patients with venous thromboembolism: a randomized controlled trial | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |